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in any medium, provided the original work is properly citeModels of sepsis have been instructive in understanding the sequence of events in
animals and, to an extent, in humans with sepsis. Events developing early in sepsisggest that a hyperinflammatory state exists, accompanied by a buildup of
idants in tissues reflective of a redox imbalance. Development of immunosup-
ssion and degraded innate and adaptive immune responses are well-established
mplications of sepsis. In addition, there is robust activation of the complement
tem, which contributes to the harmful effects of sepsis. These events appear to be
ociated with development of multiorgan failure. The relevance of animal models
sepsis to human sepsis and the failure of human clinical trials are discussed,
ether with suggestions as to how clinical trial design might be improved.Introduction
Sepsis is a clinical condition that was
originally assumed to be a systemic
response to bacterial infection, but it is
now clear that other infectious agents
(e.g. viral, fungal and parasitic organ-
isms) can also trigger sepsis. Sepsis can
develop secondary to release of var-
ious bacterial components [e.g. lipo-polysaccharide (LPS) from Gram negative bacteria, lipoteichoic
acid from Gram positive bacteria] that interact with toll-like
receptors (TLRs) to trigger inflammatory responses. More
recently, it has been discovered in cases of ‘sterile infection’
that a sepsis-like condition can also develop (Chen & Nunez,
2010). Examples of ‘sterile infection’ resulting in sepsis-like
responses include severe non-penetrating polytrauma (such as
multiple bone fractures and soft tissue injury), ischemia-
perfusion injury and haemorrhagic shock. In such cases, the
TLR system is also activated. In bacterial sepsis, the agonists for
TLRs are referred to as pathogen-associated molecular patterns
(PAMPs; Bianchi, 2007; Zipfel & Robatzek, 2010; Fig 1). PAMPs
are exogenous signals usually derived from infectious agents
and are interactive with pattern recognition receptors (PRRs)
including TLRs (present on cell surfaces and intracellularly) and
NOD receptors (present in the cytosol) involving numerous cell
types. Products released in ‘sterile sepsis’ are referred to as
danger-associated molecular patterns (DAMPs) that can trigger
inflammatory responses often via interaction with TLRs. DAMPs
include endogenous danger signals such as DNA, histones, heat
shock proteins, hyaluronins and heparin sulphate released from
damaged or necrotic cells and other products (Fig 1). A subset ofal School, Ann Arbor,
1 734 764 4308;
Ltd on behalf of EMBO. This
C BY 3.0), which permits u
d.DAMPs are the ‘alarmins’ that were recently described (Bianchi,
2007; Oppenheim et al, 2007; Yang et al, 2009) and include cell
constituents such as granulolysins, defensins, lactoferrin,
cathepsin G, HMGB1, urate crystals, ATP, etc. Some DAMPs
are enzymes (e.g. ATPases). Other DAMPs, such as HMGB1, are
peptides reactive with TLRs and other receptors. When DAMPs
appear extracellularly, they react with cell surface receptors or
with other proteins or substrates (e.g. ATPases) to trigger
inflammatory responses. Intracellular TLRs (3,7,9) react with
double or single stranded RNA. DAMPs have also been shown to
play roles in inflammatory responses following ischemia/
reperfusion injury in the heart, kidneys, liver and lungs (Pardo
et al, 2008). Collectively, sufficient amounts of DAMPs can
trigger a sepsis-like response resulting in a ‘cytokine storm’
[defined as presence of proinflammatory cytokines/chemokines
in plasma and also referred to as the systemic inflammatory
response syndrome (SIRS)].
In spite of a great deal of investment of time and money in
basic and clinical research in sepsis, including more than 40
clinical trials in septic humans, it is disconcerting that there is no
FDA-approved drug for use in sepsis. Recently, Xygris
(recombinant activated protein C) and Eritoran (an inhibitor
of TLR4) were withdrawn because of lack of clinical efficacy in
sepsis (Angus, 2011). This has caused great consternation in the
investigative community and has resulted in large pharmaceu-
tical companies being very risk-adverse for investing in drug
development and clinical trials in sepsis. It is not entirely clearis an open access article under
se, distribution and reproduction
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be the relevance of animal models as surrogates of human
sepsis. Some of the difficulty may also be in clinical trial design,
both of which are described in this review.
Sepsis in humans is linked to the presence of an infectious
organism in approximately 50% of cases. This calculation is
probably an underestimate due to the fact that by the time
patients have been admitted to the intensive care unit (ICU),
they are often on ventilator support and on vasopressors to
maintain adequate blood pressure and often have already been
treated with broad spectrum antibiotics before admission to the
ICU, complicating the ability to identify a causative organism.
Clinically, sepsis has been classified as: sepsis, severe sepsis
(with SIRS), followed by the presence of multiorgan dysfunction
(MOF), and septic shock (Tang et al, 2010). Progression of sepsis
may be due to the inability to contain infectious agents, an
example being a leak at a surgical anastomotic site in the colon.Glossary
Cecal ligation and puncture (CLP)
Widely used experimental model for sepsis, in which sepsis originates from
a polymicrobial infectious focus within the abdominal cavity, followed by
bacterial translocation into the blood compartment, which then triggers a
systemic inflammatory response.
Chemokines
A family of small cytokines, which induce directed chemotaxis in nearby
responsive cells (chemotactic cytokines).
Complement
Part of the innate immune system; a group of proteins present in blood
plasma and tissue fluid, which combine with an antigen–antibody complex
to induce the lysis of foreign cells.
Cytokines
Intercellular protein mediators released by immune cells to regulate the
immune response.
Danger-associated molecular patterns (DAMPs)
Also known as damage-associated molecular pattern molecules; mole-
cules, often nuclear or cytosolic proteins like HMGB1, that can initiate and
perpetuate immune response in the non-infectious inflammatory response.
Endotoxemia
The presence of endotoxins in the blood, which may cause haemorrhages,
necrosis of the kidneys and shock.
Hyperdynamic phase
Early phase of sepsis characterized by increased cardiac output,
tachycardia, fever, leukocytosis (neutrophilia).
Hypodynamic phase
Late phase of sepsis characterized by reduced cardiac output, bradycardia,
hypotension, hypothermia, leukopenia.
Immunomodulators
Components that can either enhance or suppress immune responses.
Immunostimulants
Agents that will bring about increased immune responsiveness, especially
in situations in which immune defenses (whether innate and/or adaptive)
have been degraded.
Multiorgan failure
Also known as multiple organ dysfunction syndrome or multisystem
organ failure; the presence of altered organ function in a patient who is
EMBO Mol Med (2012) 4, 1234–1243 Sepsis can also progress because of release of PAMPs or DAMPs.
Whatever triggered development of sepsis, the ensuing result is
development of SIRS, together with tissue buildup of reactive
oxygen species [ROS; including superoxide anion (O2),
H2O2, and myeloperoxidase products of H2O2, and the hydroxyl
radical (HO
.
)]. Reactive nitrogen species [RNS; such as NO
.
(nitric oxide) and peroxynitrite anion (ONOO
.
)] are also
produced. ROS and RNS are reactive with proteins, lipids and
DNA, forming adducts. ROS can eventually form a variety of
products such as exocyclic ethano-DNA adducts with de-
oxyadenosine or deoxycytidine (Fang, 2004). In the case of
DNA, this can ultimately lead to DNA strand breaks, which then
activates the repair enzyme, polyadenosine ribose polymerase
(PARP). PARP activation can cause substantial depletion
of mitochondrial ATP (Angus, 2010) resulting in defective
mitochondrial transfer of electrons and contributing to the
buildup of ROS.acutely ill and in whom homeostasis cannot be maintained without
intervention.
Pathogen-associated molecular patterns (PAMPs)
Pathogen-derived molecules recognized by cells of the innate immune
response that initiate and perpetuate the infectious inflammatory
response.
Reactive nitrogen species (RNS)
Family of antimicrobial molecules derived from nitric oxide (
.
NO) and
superoxide (O:2 ) produced via the enzymatic activity of inducible nitric
oxide synthase 2 (NOS2) and NADPH oxidase, respectively.
Reactive oxygen species (ROS)
Oxygen radicals that are mainly produced by the mitochondrial respiratory
chain. In excess, they can cause intracellular and mitochondrial damage,
which promotes cell death.
Sepsis
An illness in which the body has a severe response to bacteria,
other pathogens or sterile inflammation. Stages of clinical sepsis are
sepsis (accompanied by a systemic response to infection including
fever, neutrophilia, tachycardia, increased breathing rate, etc.);
severe sepsis and systemic inflammatory response syndrome (SIRS);
multiorgan failure (MOF) involving lungs, liver, kidneys, heart; septic
shock.
Septic shock
A state of acute circulatory failure characterized by persistent arterial
hypotension despite adequate fluid resuscitation or by tissue hypoperfu-
sion unexplained by other causes.
Severe sepsis
Sepsis complicated by end-organ dysfunction, as signalled by
altered mental status, an episode of hypotension, elevated creatinine
concentration or evidence of disseminated intravascular coagulopathy.
‘Sterile’ inflammation
Inflammation as a result of trauma, ischemia-reperfusion injury or
chemically induced injury that typically occurs in the absence of any
microorganisms.
Systemic inflammatory response syndrome (SIRS)
The clinical manifestations that result from the systemic response to
infection. These include hyper- or hypothermia, elevated heart rate,
elevated respiratory rate or decreased arterial carbon dioxide tension,
abnormal white blood cell count.
2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1235
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Figure 1. Intrinsic (DAMPs) and extrinsic (PAMPs) signals develop during an infectious condition (e.g. bacterial pneumonia) that causes inflammation and
sepsis which is often associated with development of SIRS, buildup of ROS and RNS in tissues, multiorgan failure (MOF) and lethality. Receptors (PRRs) for
these signals engage both TLRs and NOD-like receptors. The listings of ligands that interact with TLRs and NOD receptors is somewhat artificial. For instance, while
HMGB1 (considered to be a DAMP) interacts with TLR4, it also interacts with TLR2 and with the receptor for advanced glycation products (RAGE). Heat shock
proteins (DAMPs) react with TLR2, TLR4 and with receptors on antigen presenting cells (CD36, a scavenger receptors). ‘Sterile’ inflammation occurs after
hemorrhagic shock, polytrauma, ischemia/reperfusion and is not usually associated with the presence of an infectious agent. In all cases, the same cascade of
downstream events seems to occur.
1236Animals in the early stages of sepsis often present with a
hyperdynamic phase [increased cardiac output, tachycardia,
fever, leukocytosis (neutrophilia)], followed, as sepsis pro-
gresses, by a hypodynamic phase (reduced cardiac output,
bradycardia, hypotension, hypothermia, leukopenia, etc.).
Several similar features occur in septic humans, but clinical
interventions such as antibiotic therapy and fluid resuscitation
make the sequence of events less definitive than those found
in animal models of sepsis. The development of MOF is
associated with dysfunction of cardiac, renal, hepatic and
respiratory organs but also involving the peripheral vasculature.
CNS dysfunction (hallucinations, somnolence, confusion,
cognitive defects, etc.) may also occur (Hermans et al, 2008;
Vincent et al, 2002; Winters et al, 2010). The development of
MOF may be related to hypoperfusion of organs due to falling
blood pressure. Whether there is a sequential linkage between
failing organs is not known. Clinically aggressive attempts
are made to treat what has triggered the septic response.
Simultaneously, supportive measures may include blood or
plasma replacement (in the case of haemorrhagic shock), as well
as infusion of resuscitative electrolyte and glucose-containing
fluids, and provision of ventilator and vasopressor support.
Typically in humans sepsis usually runs its acute course in 4–
12 days, although FDA criteria for drug efficacy require survival
data at day 28. After convalescence from sepsis, a much longer
period of observation (months to years) may be appropriate
because of persistence or onset of complications (cognitive
defects, skeletal muscle weakness, immunosuppression, etc.). 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.The causes of such complications are poorly understood
(Adrie et al, 2007; Angus, 2011; Angus et al, 2001; Clark &
Coopersmith, 2007; Cruz et al, 2009; Deitch, 2002). Another
striking feature about the longer term problems is that mortality
rate years later was much higher than that found in age-matched
individuals who had not experienced sepsis (Bagshaw, 2008).
Accordingly, sepsis presents extremely challenging clinical
problems as an acute disease but also as a long-term condition
(over years) with a grave prognosis due to reduced survival.Animal models of sepsis
Numerous models of sepsis in animals have been developed,
usually employing rodents, since the use of larger animals
(rabbits, sheep, pigs and subhuman primates) would require
access to ICU-type facilities with around-the-clock coverage for
days or weeks. The most common models of experimental
sepsis include injection (local or systemic) of live bacteria, a
commonly used organism being Escherichia coli. Other models
of sepsis include extrusion of faecal contents from surgically
manipulated areas of gut [usually cecum, cecal ligation and
puncture (CLP)]; the colon ascendens stent peritonitis (CASP)
which causes an intraperitoneal leak of faeces, leading to
polymicrobial sepsis, similar to what is seen in the CLP model;
instillation of live bacteria into lung (often Pseudomonas sp. or
Klebsiella sp.); and injection (local or systemic) of products
of bacteria (PAMPs, see Fig 1), such as endotoxin (LPS) orEMBO Mol Med (2012) 4, 1234–1243
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disadvantages. The CLP model has been widely employed in rats
and mice and induces many of the features of human sepsis and
has been referred to as the ‘gold standard’ for the study of sepsis
(Dejager et al, 2011). However, the CLP model has several
complexities that influence outcomes: effects of age and gender;
the tremendous heterogeneity of immune and inflammatory
responses related to genetic strains of mice; influences of
therapeutic interventions; and dramatic differences in outcomes
based on technical approaches (number of cecal punctures,
needle size, amount of cecum ligated; Rittirsch et al, 2009).
There are many issues dealing with the choice of an animal
model and its relevance to human sepsis, such as:1. DEMramatic differences in the timing of responses (such as
when cytokine/chemokine levels peak in plasma). In rodents
injected with LPS, plasma mediators peak in the first several
hours versus in CLP with mediator peaks much more slowly
developing, over the first 48 h (Remick et al, 1995; Remick &
Ward, 2005; Rittirsch et al, 2007). To what extent can these
two models be compared is questionable as is whether either
model mimics events developing in humans with sepsis.2. While Klebsiella sp. or Pseudomonas sp.-induced pneumonia
in mice produces a sepsis pattern similar to that found in
humans with Gram-negative bacterial pneumonia, to what
extent do the symptoms in mice reflect those found in
humans with sepsis following bacterial pneumonia? Are
patterns of sepsis development due to Gram-negative
bacteria similar to or different from bacterial pneumonia
and sepsis induced with Gram-positive bacteria (e.g.
Streptococcal sp., Staphylococcus aureus)? Does sepsis
induced by Gram-negative bacterial pneumonia follow the
same pathophysiological pathways occurring in sepsis
related to Gram-negative bacterial peritonitis?3. Does sepsis triggered by bacterial infection follow the same
pathophysiology as found in the case of ‘sterile’ inflammation
(such as seen after non-penetrating polytrauma or hemor-
rhagic shock)?4. Given the difficulties in consistently demonstrating the
presence of LPS in plasma from septic humans (Opal, 2002),
are the animal models of endotoxemia relevant to human
sepsis?
Numerous reports comprehensively review models of animal
sepsis and the extent to which they may or may not be relevant
to human sepsis (Buras et al, 2005; Dejager et al, 2011; Doi et al,
2009; Fink, 2008; Zanotti-Cavazzoni & Goldfarb, 2009). Other
reviews emphasize the constraints of animal models when
extrapolating such data to sepsis in humans (Dyson & Singer,
2009; Marshall, 2008; Rittirsch et al, 2007). There are reports
suggesting that human septic males have higher mortality rates
(Adrie et al, 2007; Angus et al, 2001; Schroder et al, 1998;
Wichmann et al, 2000), but such reports are not consistent with
others (Eachempati et al, 1999). In septic mice, there is also
evidence that males have worse outcomes than female mice
(reviewed in Choudhry et al, 2006). In each experimental model,
it is important to document these variables since they canBO Mol Med (2012) 4, 1234–1243 significantly affect the results. One animal manipulation that has
been little employed to date in experimental sepsis is the use of
‘humanized mice’ in which the immune and haematopoietic
systems have been replaced by human cells (Devoy et al, 2012).
The use of these mice, which are extremely expensive, may
provide important insights that will have greater relevance to
human sepsis than the traditional use of ‘knockout’ or ‘knockin’
mice.Controversies about sepsis as a hyperinflammatory
state and implications for human clinical trials
As summarized in Fig 2, there are many features in sepsis that
would suggest a hyper-inflammatory state. In the setting of CLP,
endothelial cells showed marked increases in surface ICAM-1
(which would favour neutrophil adherence and subsequent
transmigration) and expression of VCAM-1 on endothelial cells
(an adhesion molecule for lymphocytes and monocytes). CLP
mice were evaluated for endothelial ICAM-1 and VCAM-1 levels
using vasculature binding of 125I-antibodies. Progressive
increases in levels of vascular ICAM-1 occurred following
CLP, and such changes being found in numerous organs (Laudes
et al, 2004). Concomitantly, there were also increases in
vascular VCAM-1. Endothelial cells showed substantial
increases in ICAM-1 mRNA during development of sepsis
(Wu et al, 2002). Early in sepsis there was increased tissue
content of MPO in a variety of organs. MPO is a relatively
specific indicator for PMN presence (Guo & Ward, 2005).
Furthermore, sepsis caused a ‘gain of function’ in neutrophils,
with increased levels of b2 integrins (e.g. CD11b/CD18; which
indicates activation) together with increased levels of b1
integrin, inferring that these cells would now be interactive
with connective tissue matrix proteins (Speyer et al, 2004;
Speyer & Ward, 2011). Also, blood PMNs during sepsis acquired
increased expression of mRNA for CCR2 and CCR5, correlating
with enhanced ligand binding and intensified in vitro chemo-
tactic responses to various chemokines. Together, these data are
consistent with a hyper-inflammatory state developing in
rodents after CLP, the duration of which is unknown.
The cell sources for mediators of the SIRS response are chiefly
derivatives of myeloid cells (e.g. PMNs, macrophages, mono-
cytes, dendritic cells) but also non-myeloid cells (e.g. hepato-
cytes, alveolar epithelial cells, cardiomyocytes, etc). The
downstream effects of the SIRS mediators are not clearly
defined. While cytokine/chemokine interaction with receptors
in various organs may lead to organ injury, there is no direct
evidence to support such conclusions. The problem in precisely
defining the role of these proinflammatory mediators is
highlighted by the substantial overlap and functional redun-
dancy of these mediators. In addition, there are several
individual receptors that can bind with more than one ligand.
For all of these reasons, the strategy in sepsis to target a single
cytokine or chemokine for neutralization would not be expected
to be successful. This may explain the general failure in human
clinical trials when a single mediator was selected as a target for
blockade, such as antibody neutralization of TNF-a, blocking of2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1237
Review www.embomolmed.org





(elevated plasma levels of proinflammatory
cytokines/chemokines)
Leukocyte accumulation in tissue/organs
Multi-organ failure (MOF)
Lethality
The hyperinflammatory response in sepsis
Elevated levels of ICAM-1 and VCAM-1 
on endothelial cells
Enhanced levels of chemokine receptors 
on PMNs
Increased adhesion of PMNs, monocytes, 
lymphocytes to endothelial cells
Enhanced emigration of PMNs, monocytes, 
lymphocytes to tissues
Figure 2. Evidence of hyperinflammatory responses developing in the
setting of sepsis. The early event is appearance of ROS and RNS in tissues
together with numerous proinflammatory cytokines and chemokines in
plasma (SIRS), accompanied by other manifestations of a robust inflammatory
response (appearance of activation markers on PMNs, such as CD11b/CD18),
increased levels of adhesion molecules (ICAM-1, VCAM-1) on endothelial cells,
and elevated levels of chemokine receptors on PMNs, all of which implies a
‘gain of function’, resulting in a buildup in tissues of PMNs, monocytes,
lymphocytes and dendritic cells in tissues. Development of activation
molecules as well as chemokine receptors on leukocytes and adhesion
molecules on endothelial cells would facilitate leukocyte buildup, perhaps
contributing to the damage of multiple organs by facilitating the recruitment
of inflammatory cells, which may be linked to MOF.
1238TNF-a with soluble TNF-aR, or blocking of IL-1b by IL-1
receptor antagonist (reviewed in Marshall, 2008 and Vincent
et al, 2002). Perhaps blockade of TNF-a or IL-1b also removed
the protective function of these mediators in innate immune
defenses.
The earlier literature has suggested that sepsis in rodents is
associated with a breakdown in the gut epithelial barrier,
resulting in translation of intact bacteria and their products
(such as LPS) into the blood stream and the gut lymphatics,
causing a systemic sepsis response (Deitch, 2002). In addition, it
is possible that the gut also produces factors that compromise
the blood-brain barrier (Banks, 2008). Based on such informa-
tion, the gut has been described as the ‘motor’ of critical illness 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.(Clark & Coopersmith, 2007). This theory is appealing, but
because sepsis can also develop in the absence of infectious agents
(as in ischemia-reperfusion or haemorrhagic shock) this may
limit the applications of the bacterial translocation hypothesis.
Neutralization of TNF-a was highly protective and greatly
improved survival in endotoxemic mice (Beutler et al, 1985).
However, in CLP, the results using a neutralizing antibody to
TNF-a showed no consistent evidence of protection (Eskandari
et al, 1992; Remick et al, 1995). There are substantial differences
in plasma/serum levels of mediators and the time when they
peak in plasma of mice during endotoxemia as compared to CLP
(Deitch, 1998; Fink & Heard, 1990; Schultz & van der Poll, 2002),
raising the question about whether endotoxemia and CLP follow
different pathophysiological pathways.Neutralization or removal of plasma
cytokines/chemokines in the septic state
As indicated above, development of SIRS in sepsis refers to the
presence in plasma of proinflammatory mediators, such as
TNF-a, IL-1b, IL-6, IL-18, IL-8 as well as MCP-1 (CCL-2), MIP-1a
(CCL3), MIP-1b (CCL4), etc. Some of these mediators
are chemotactic for PMNs and monocytes, while others are
chemotactic for T cells. Biological responses induced by these
mediators are quite pleiotropic. SIRS is also associated with
elevated levels of ROS and RNS in organs as sepsis progresses to
‘severe sepsis’ and development of septic shock and multi-organ
failure (Fig 2). The temporal patterns of the SIRS response, and
the precise relationships between redox imbalance, develop-
ment of SIRS and subsequent progression of MOF are uncertain.
While limited data (see above) suggest that SIRS does not fully
develop if the redox imbalance is at least partially reversed, it is
still questionable as to whether SIRS can be linked to redox
imbalance. It is assumed but not proven that the plasma
mediators may lead to the buildup of MPO as well as ROS and
RNS levels in various organs which eventually fail in sepsis. In
contrast, it has been suggested that SIRS may reflect inadequate
removal of the infectious agent responsible for the development
of sepsis (Angus, 2011), although in the case of ‘sterile’
inflammation after polytrauma, ischemia-reperfusion injury or
haemorrhagic shock, the role of an infectious agent is not likely.
Regardless of the cause of SIRS and subsequent responses, bulk
removal of cytokines/chemokines from plasma might provide
clues as to the roles of these mediators. Haemodialysis has not
been shown to be effective in removal of plasma cytokines/
chemokines (Cole et al, 2002; Sieberth & Kierdorf, 1999). In
2002, ex vivo removal using an extracorporeal circuit was
employed together with large-pore haemofiltration and sorbent
adsorption. Fresh human blood had been activated with LPS.
This blood was then recirculated through the device for 6 h.
Over the first few hours, significant reductions in IL-1, IL-6, IL-8
and TNF-a occurred (Cole et al, 2002). Haemofiltration devices
have been employed for several decades, being used chiefly in
patients with acute renal failure (ARF). In the earlier models of
continuous haemofiltration, reductions in plasma TNF-a were
transient (Sieberth & Kierdorf, 1999). Haemofiltration through aEMBO Mol Med (2012) 4, 1234–1243
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reductions of IL-1, IL-6, IL-10, IL-18, TNF-a and other mediators
(Winchester et al, 2003). Apheresis (use of columns to remove
selective components of blood) employing immobilized poly-
myxin B fibre columns was able to remove LPS from human
blood (Shimizu et al, 2006), but for the reasons listed above, this
may not be an especially effective strategy for the treatment of
many humans with sepsis who have Gram-positive sepsis. In
multicentre clinical trials in Italy involving patients with severe
sepsis or septic shock associated with intra-abdominal Gram-
negative infections, polymyxin B haemoperfusion appeared to
significantly improve haemodynamics and organ dysfunction
(Cruz et al, 2009). Recently, porous carbon particles that were
blood compatible were shown to rapidly remove TNF-a, IL-6
and IL-1b from plasma (Yachamaneni et al, 2010). Continuous
haemofiltration has been employed using a polymethylmetha-
crylate membrane haemofilter in 43 patients with septic shock.
Plasma levels of IL-6 were reduced and haemodynamic indices
were improved, together with increased urine output and
reduced levels of blood lactate (Nakada et al, 2008). Obviously,
further clinical studies are needed together with determinations
of precisely what mediators were removed and for how long.
Concerns include the highly invasive nature of many of these
techniques. The ultimate, critical question is: to what extent will
mediator removal from septic human blood reduce the
progression to septic shock and multi-organ failure?
Finally, there has been consideration for the use of anti-
inflammatory corticosteroids/glucocorticoids in the setting of
sepsis. While early clinical studies suggested beneficial effects of
steroids in sepsis (Schumer, 1976), subsequent studies failed to
show any benefit with high doses of steroids. Recent studies
have suggested that low doses of hydrocortisone may have some
beneficial effects in sepsis (reviewed in Vincent et al, 2002) but
in general there has been limited enthusiasm for the use of
steroids in septic humans. In addition, a recent report cautions
that systemic corticosteroid treatment should be very cautiously
employed in critically ill patients in ICUs because of greatly
increased risk of death due to bacterial pneumonias (Ranzani
et al, 2012).Use of immunostimulants in sepsis
The term ‘immunostimulants’ connotes agents that will bring
about increased immune responsiveness, especially in situa-
tions in which immune defenses (whether innate and/or
adaptive) have been degraded. Immunomodulators are compo-
nents that can either enhance or suppress immune responses.
Immunostimulants have been used in patients with progressive
cancer in attempts to boost the immune system and suppress
tumour progression. Although IFN-g and IL-2 have been used to
enhance immune responsiveness, their use has been greatly
limited due to intense toxicity at doses employed clinically.
Development of immunosuppression early in the onset of
sepsis in humans is well established. Most patients diagnosed
with sepsis (only 50% having a confirmed presence of an
infectious organism by the time the diagnosis of sepsis has beenEMBO Mol Med (2012) 4, 1234–1243 made) are already severely lymphopenic. Recent studies
indicate that apoptosis of T and B cells is often well advanced
at the time of admission to the ICU (Boomer et al, 2011;
Hotchkiss & Karl, 2003; Russell, 2006). The pathways of
apoptosis in sepsis may involve activation of the extrinsic (TNF-
a/TNFR and Fas/FasL) and/or intrinsic (mitochondrial) path-
ways, the final steps being activation of caspases that cause
apoptosis of T and B cells. The studies of the Hotchkiss group
showed that synthetic, broad spectrum inhibitors of apoptosis
(such as Z-VAD), if given before onset of CLP in mice, would
reduce caspase activation and cause diminished intensity of
lymphoid cell apoptosis, resulting in improved survival after
CLP (Hotchkiss et al, 1999). It was also shown that use of
Z-VAD-FMK, a broad spectrum caspase inhibitor, reduced plasma
levels of HMGB1, a mediator known to be harmful in the setting
of endotoxemia. Precisely how Z-VAD-FMK caused reduction of
HMGB1 is not clear. However, commencement of the anti-
apoptotic therapy after the onset of CLP had marginal effects.
Because of these difficulties, there has been interest in the use
of immunostimulants in septic humans, with the hope that they
might at least partially restore immune competence through
regeneration of the lymphoid system decimated by extensive
apoptosis of T and B cells (Unsinger et al, 2010). IL-7 is a potent
anti-apoptotic cytokine that promotes lymphocyte survival and
is a growth-promoting factor for both T and B cells. Its toxicity is
very limited. When given 90 min after induction of CLP in mice,
IL-7 improved survival and reduced apoptosis of CD4 and CD8
positive cells, restored IFN-g production, and improved immune
effector cell recruitment. This treatment also restored the ability
of CLP mice to express delayed-type hypersensitivity responses
in skin. Increased expression of the major anti-apoptotic protein,
Bcl-2, in lymphocytes also occurred. IL-7 induces proliferation of
naı̈ve CD4 and CD8 T cells (Fry & Mackall, 2005; Geiselhart et al,
2001) and has been used in clinical trials in cancer patients in an
attempt to bolster immune defenses (Sportes et al, 2008).
Clinical trials using IL-7 in humans with sepsis have not yet
commenced, but such interventions may hold promise on the
basis of results in CLP mice and increases in blood CD4þ and
CD8þ lymphocytes in HIV patients (Banks, 2008).
Another potential immunostimulant for septic patients is
IL-15. This cytokine has biochemical similarity to IL-2. It is
produced by macrophages and induces proliferation of NK cells
and other cells of the innate immune system. It regulates T-cell
activation and proliferation and induces Bcl-2 to render T cells
resistant to apoptosis. In experimental animals, over-expression
of IL-15 protected against E. coli induced shock, perhaps because
levels of TNF-a were reduced (Hiromatsu et al, 2003). Based on
these features, IL-15 may also be a candidate for reversal of
immunosuppression in sepsis.
The broad area of immunostimulants, including for use in
sepsis, has been recently reviewed (Webster & Galley, 2009).
Many of the strategies (glucocorticoids, sedatives, opioids and
corticosteroids) have already been used in sepsis and appear to
have limited beneficial effects. Other interventions provide
evidence for enhanced immune responses including glucans
(Gertsch et al, 2011; Vetvicka, 2011) and muramyl peptides
(O’Reilly & Zak, 1992). While most of these immunostimulants2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1239
Review www.embomolmed.org
New approaches to the study of sepsis
1240have been used to treat patients with malignant tumours,
there is little information on whether they would be useful in
sepsis to rescue the immune system or reverse the state of
immunosuppression.Neutralization of C5a and C5a receptors in sepsis
As indicated above, in the 1980s it was found that endotoxemic
mice responded with brief, high levels of TNF-a in plasma and
that systemic neutralization of TNF-a significantly improved
survival (Beutler et al, 1985). In baboons that had been infused
with live E. coli, a similar strategy for neutralization of TNF-a
produced beneficial effects and improved survival (Tracey et al,
1987). When monkeys that developed septic shock after
infusion of live E. coli were pre-treated with rabbit polyclonal
IgG that neutralized C5a, there were suggestions of benefit
(based on clinical findings, biochemical and metabolic para-
meters and mortality), but the small number of animals
precluded the drawing of statistically significant conclusions
(Stevens et al, 1986). Experimental evidence (chiefly from our
own research laboratories) has provided evidence for a key role
of C5a and its receptors (C5aR, C5L2) in the progression of
experimental sepsis (CLP) in rodents (reviewed in Ward, 2010).
In sepsis involving rodents or humans, there is robust activation
of complement and the appearance in plasma of the anaphy-
latoxins, C3a and C5a. The latter binds with high affinity to its

















Figure 3. Molecular models of C5a and C5aR in which its ligand, C5a, is also
A. C5a is a rather oxidant-resistant glycosylated peptide with antiparallel helica
B. The interaction of C5a with C5aR (CD88) triggers series of responses initiated
engagement and activation of the signalling molecules, RAS, RAF-1, MEK1/2 and
linked to the translocation of cytosolic subunits of NOX2 to the plasma membra
superoxide anion (O2) and generation of H2O2, which accounts for the major b
result in inflammatory injury of organs.
 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.phils, monocytes and macrophages) but also on a variety of non-
myeloid derived cells [such as endothelial cells and cardio-
myocytes (Gerard et al, 2005; Monk et al, 2007; Okinaga et al,
2003)]. The structures of C5a and the C5a receptor (C5aR, CD88)
are shown in Fig 3. Human C5a is a 74 amino acid glycoprotein
(while rat C5a has 77 residues) with complex anti-parallel
helical structures (Fig 3A). C5a is released from the a chain of
the parent molecule, C5, following activation of complement,
whether by the classical, alternative or lectin pathways. PMNs
have high numbers of binding sites for C5a (circa 60,000 per
cell), while monocytes, macrophages and endothelial cells have
far fewer binding sites. C5aR is a 45 kDa protein, rhodopsin-type
transmembrane spanning structure that is coupled to G proteins
in the cytosol (Fig 3B). Activation of C5aR by C5a is followed by
activation of the following signalling proteins: RAS, RAF-1,
MEK1/2 and ERK1/2, unleashing a series of functional
responses, including activation of NADPH oxidase (NOX2).
Details are provided elsewhere (Ward, 2004).
In PMNs, C5a triggers G protein binding to the C terminal
region of C5aR, resulting in a cascade of signalling events
(described above), with biological responses such as priming for
accentuated cell responses to a second stimulus (e.g. LPS,
Wrann et al, 2007). Responses to C5a via C5aR also include
intracellular Ca2þ transients, secretion of cytoplasmic granule
contents, activation of NADPH oxidase which results in
production of ROS [e.g. superoxide anion (O2), H2O2, etc.],
chemotactic responses and a variety of other functional





































by interaction of the cytoplasmic tail of C5aR with G-proteins, followed by
ERK1/2. An important response is activation of NADPH oxidase (NOX2) which is
ne where NOX2 is assembled, facilitating electron transport and production of
actericidal activity of activated PMNs. The presence of activated PMNs would




Animal models: As emphasized in the text, rodent models of sepsis
have often employed the CLP model. The outcomes are vitally
dependent on technical details (number of cecal punctures, needle
gauge, amount of cecum ligated). The critical question is the
relevance of findings in the CLP model to events developing in
human sepsis. No consensus has been reached on this matter.
Interventions that were protective in CLP mice were not beneficial in
septic humans. One possibility that might yield useful data would be
using the CLP model in ‘humanized mice’ that have human
myelopoietic and lymphoid cells, use of which might provide data
more relevant to septic humans.
Another issue is the relevance of the endotoxemia mouse model to
humans with sepsis. There are many reasons to question the
relevance of the endotoxemia mouse model to humans with sepsis,
as described in the text. While endotoxemia in both mice and in
humans unleashes a cascade of similar responses (complement
activation, neutropenia followed by neutrophilia, activation of the
clotting cascade, etc.), such outcomes may be relevant to septic
humans with Gram-negative infections but there are serious
questions as to whether this information applies to humans withprotective responses in the setting of infectious agents or after
organ injury (e.g. trauma, ischemia/reperfusion injury, etc.). In
contrast, the second C5a receptor, C5L2, contains substitutions
in C terminal amino acids such that there is no interaction with
G proteins (Monk et al, 2007), with no [Ca2þ]i transients
when these receptors interact with C5a or C5a des arg. It is still
controversial as to whether C5L2 receptor activation after
contact with ligand induces signalling responses that result
in activation of MEK1/2 and ERK1/2 (Chen et al, 2007) or
whether C5L2 simply functions as a ‘default’ receptor. There is
controversy regarding whether C5L2 in the ‘resting’ PMN is
expressed on the cell surface or only within the cytosol (Monk
et al, 2007). To date, understanding C5L2 function is uncertain.
Neutralization (with antibody) or genetic absence of C5aR or
C5L2 reduces the intensity of CLP or endotoxemia in mice
as reflected in survival curves (Chen et al, 2007; Guo & Ward,
2005; Rittirsch et al, 2008). When both C5a receptors were
unavailable, survival rates in CLP mice were improved and
plasma levels of cytokines/chemokines were significantly
reduced, suggesting that activation of both C5a receptors occurs
in CLP and results in harmful outcomes (Rittirsch et al, 2008).
Blockade (with neutralizing antibodies) or genetic absence of
C5aR or C5L2 improved survival in CLP or endotoxemic mice
(Chen et al, 2007; Guo & Ward, 2005; Rittirsch et al, 2008).
With respect to the ability of C5a neutralizing antibodies to
protect CLP rats from lethality, three different regions of rat C5a
were selected as targets. These included the N-terminal (N)
region (residues 1–16), the middle (M) region of C5a (residues
17–36) and the C terminal region (residues 58–77). Rabbit
polyclonal IgG antibodies obtained were affinity-purified as
antigen (C5a peptide)-specific IgGs. Antibody to the N region
produced intense bands on Western blot analysis but had no
protective effects in CLP rats, whereas antibodies to the M and C
terminal regions of rat C5a were highly protective (Huber-Lang
et al, 2001; Rittirsch et al, 2008). It was also shown that delayed
administration of these antibodies, up to 12 h after CLP, still
provided protective effects. What is the most desirable target for
treatment in sepsis (C5a, C5aR or C5L2)? Since the two C5a
receptors are also expressed on a variety of non-myeloid cells/
tissues, it is unclear if antibodies to these receptors might have
unintended consequences such as agonist functions, raising the
question about the duration of C5a receptor blockade in vivo.
There are small molecular weight molecules with antagonistic
effects on C5a receptors, but their pharmacokinetics character-
istics are inadequately known, and they have only been applied
in humans in very limited circumstances (rheumatoid arthritis)
without clinical efficacy (Woodruff et al, 2011). Taken together,
this information suggests that targeting C5a rather than C5a
receptors may be the desirable option for treatment of humans
with sepsis.
Gram-positive sepsis (e.g. Streptococcal pneumoniae, Staphylococcus
aureus).
Future directions: On the basis of the failures in more than 40
clinical trials in humans with sepsis, a major problem is that the
current lethality rate is 25–30%, indicating that 70% of patients will
not likely show benefit from new drugs. As indicated in the text,
there may be strategies for patient recruitment that would permit
doing much smaller clinical trials.The future
As mentioned in the Introduction section, there is a desperate
need for new, effective drugs for treatment of humans with
sepsis. Based on more than 40 failed clinical trials in septicEMBO Mol Med (2012) 4, 1234–1243 humans, it is clear that extrapolation of data obtained from
septic (CLP) or endotoxemic rodents does not necessarily
provide reliable predictions for septic humans. One possibility
is that the pathophysiology of sepsis in humans is different
from events occurring in septic rodents. As indicated above,
resuscitative measures in humans may alter the pathophysio-
logical manifestations of sepsis. Most CLP or endotoxemic
studies employ 25 g C57Bl/6 male mice which are 1–2 months
old. This would be roughly equivalent to young humans
(approximately 4 years old), while in most clinical trials the
mean age of patients is 60 years. Accordingly, this may be one
reason why animal data cannot be reliably extrapolated to
humans. Another possibility is that clinical trial design in
humans has been far less than optimal. For instance, when only
about 30% of all septic patients will expire in the course of
28 days, this means that nearly 70% of patients will not show
benefit with new drug interventions. Such a reality means that
the number of enrollees needs to be very large (thousands) in
order to achieve statistical significance for a drug that is
ultimately shown to be efficacious. Another issue with clinical
trial design is that better selection of septic patients (such as
those entering into septic shock) might allow for much smaller
clinical trials. Obviously, we do not have enough information to
predict if a cohort would demonstrate beneficial effects of drug
interventions, or if the onset of septic shock represents an
advanced point of sepsis that is too late for rescue. Needless to
say, we need much more information about the pathophysiology
of sepsis and how we can most effectively intervene and at what
time after the diagnosis of sepsis. Other considerations that need
to be factored in relate to co-morbidities (diabetes melitis, obesity,
cardiovascular disease, hypertension, etc.) that are common in
septic patients (usually approximately 60 years of age).2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1241
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